NASDAQ · PRAX
Praxis Precision Medicines, Inc.
$288.62+$3.14 (+1.1%)
Praxis Precision Medicines, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.5% below the high.
Loading market information…
NASDAQ · RAPP · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Rapport Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 54.26% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Rapport Therapeutics, Inc. Common Stock’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$1.20. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Rapport Therapeutics, Inc. Common Stock’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.68+11.69% vs estimate |
| $0.00 |
| Q4 2024 | Mar 11, 2025 | -$0.57+8.06% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.50+12.28% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 9 contributors · Median target $66.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$288.62+$3.14 (+1.1%)
Praxis Precision Medicines, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.5% below the high.
$143.45-$0.06 (-0.04%)
Axsome Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.87% below the high.
$20.76+$0.44 (+2.17%)
Acadia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.95% below the high.
$40.15+$0.32 (+0.8%)
LB Pharmaceuticals Inc Common Stock’s quoted price sits in the upper half of its reported 52-week range, 19.96% below the high.
$21.10+$0.72 (+3.53%)
Seaport Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 25.65% below the high.
$23.47+$0.14 (+0.6%)
Alto Neuroscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.38% below the high.
$7.72-$0.26 (-3.26%)
MapLight Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.91% below the high.
$9.33+$0.18 (+1.97%)
Contineum Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.55% below the high.
